Erythropoietin Drugs Have Been Approved For Chemotherapy-Induced Anaemia
Erythropoietin Drugs A glycoprotein hormone called erythropoietin (EPO) or hematopoietin stimulates the erythropoiesis process, which results in the creation of red blood cells in the bone marrow. The medicine erythropoietin was created with the intention of treating anaemic conditions brought on by dialysis and treatments for end stage renal disease (ESRD). Erythropoietin Drugs have been approved for chemotherapy-induced anaemia, which follows ESRD anaemia. Original biopharmaceutical companies focused on ART-induced anaemia after post-abbreviated new drug application (ANDA) approvals and the high success rate of EPO applications for chemotherapy-induced anaemia (among HIV patients). Drugs that mimic erythropoietin, a naturally occurring hormone secreted from the kidney, aid in the production of red blood cells (RBC) by enhancing the activity of bone marrow tissues. Raising the RBC count raises the blood's haemoglobin concentration, which helps the body's tissues carry eno...